Etretinate is a second-generation retinoid that was used as an active pharmaceutical ingredient in medications for severe psoriasis. It was developed by Hoffmann–La Roche and approved by the FDA in 1986, but later withdrawn from several markets due to a high risk of birth defects.
콘텐츠 범위: 이 페이지의 정보는 화학물질 식별 및 산업 공급·연구개발·제조 맥락을 대상으로 합니다. 치료 효능 주장, 의료 조언 또는 의약품 사용 지침에 해당하지 않습니다.
이 화합물을 구매하거나 공급하시겠습니까?
재고를 등록하거나 구매 요청을 게시하세요
CAS 54350-48-0
(2E,4E,6E,8E)-Butyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
Intermediates of Acitretin
(2E,4E,6E,8E)-Butyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
Pharmaceutical impurity reference standard
Acitretin Impurity 10
impurity reference standard for acitretin
(R)-1,2,3,4-tetrahydro-6,7-dimethoxy-1-veratrylisoquinoline hydrochloride
active pharmaceutical ingredient
Triethylenephosphoramide
active pharmaceutical ingredient
Etofylline clofibrate
active pharmaceutical ingredient
5-Aminolevulinic acid hydrochloride
active pharmaceutical ingredient
ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
HQMNCQVAMBCHCO-DJRRULDNSA-N
CCOC(=O)/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C(=C(C=C1C)OC)C)C